Advertisement

Topics

Metris Therapeutics Company Profile

16:51 EDT 19th September 2017 | BioPortfolio

Established in 1996, Metris now has several products in development. These are a treatment for endometriosis, a treatment for menorrhagia / dysmenorrhea, using a proprietary vaginal drug delivery system, and an oral treatment for chronic symptoms associated with the menopause. Metris intends to license its products to third parties for late stage clinical development and commercialisation.

Metris recognises the need to improve the clinical management of benign gynaecological conditions. Our objective is to improve the quality of life for millions of women by meeting women’s healthcare needs more effectively.

Location

515 Eskdale Road
Wokingham
Berkshire
RG41 5TU
United Kingdom

Contact

Phone: 0118 969 7266 EXT 207
Fax: 0118 969 2272
Email: david.morse@metris.co.uk


News Articles [1509 Associated News Articles listed on BioPortfolio]

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of inst...

Summit Therapeutics PLC (SMMT) and Orexigen Therapeutics (OREX) Head to Head Review

Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...

RaNA Therapeutics Relaunches as Translate Bio to Advance RNA Therapeutics

Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

M&As this week: Bioverativ Therapeutics, Horizon Pharma

Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.

Dragonfly Therapeutics names world leader in NK therapeutics as CSO

Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).

Head-To-Head Survey: Anika Therapeutics (ANIK) versus Its Peers

Anika Therapeutics is one of 45 public companies in the "Biopharmaceuticals" industry, but how does it compare to its competitors? We will compare Anika Therapeutics to related companies based on the ...

Clinical Trials [116 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1145 Associated Companies listed on BioPortfolio]

Metris Therapeutics

Established in 1996, Metris now has several products in development. These are a treatment for endometriosis, a treatment for menorrhagia / dysmenorrhea, using a proprietary vaginal drug delivery syst...

Metris B.V.

Metris was originally founded in 1994 and registered as Metris System Engineering V.O.F. In May 1999, new shareholders joined the company and the legal form was changed, resulting in it's current new ...

Metris Therapeutics Ltd.

Nil

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Metris Therapeutics" on BioPortfolio

We have published hundreds of Metris Therapeutics news stories on BioPortfolio along with dozens of Metris Therapeutics Clinical Trials and PubMed Articles about Metris Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Metris Therapeutics Companies in our database. You can also find out about relevant Metris Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Menopause
The menopause is a natural event for all women; the ovaries no longer produce estrogen and progesterone. This can be due to natural aging (usual age of onset is 51 years), or through chemotherapy and surgery on the ovaries. The changing balance of the ho...


Corporate Database Quicklinks



Searches Linking to this Company Record